Jade Biosciences, Inc 10-Q for FY2026 Q3
Jade Biosciences, Inc. (JBIO)
10-Q
2026-11-13
For: 2026-09-30
View Original
Added on
November 13, 2026
About this 10-Q
Jade Biosciences, Inc filed this 10-Q on November 13, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Jade Biosciences plans to initiate the JADE101 EVERGREEN Phase 3 trial in the fourth quarter of 2026. Net loss was $35.1 million for three months and $131.2 million for nine months ended September 30, 2026, while cash and investments totaled $475.7 million. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $35.06M
- compared with a net loss of $25.18M a year earlier
- Diluted EPS
- -$0.42
- compared with -$0.48 a year earlier